Biomarkers after stem cell transplant for neurological diseases
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial looks at biomarkers (biological signs in your blood) in people with immune-mediated neurological diseases. It compares those getting a stem cell transplant to those on high-efficacy MS treatments to understand how these therapies work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosed immune-mediated neurological disease (like multiple sclerosis) to join the active treatment group, OR have relapsing-remitting MS for the control group.
- You must be receiving either an autologous stem cell transplant (aHSCT) or a high-efficacy disease-modifying therapy for MS.
- You must be willing to give biological samples (like blood) and attend study visits for the entire follow-up period.
- You must be able to understand English and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a stem cell transplant treatment for relapsing-remitting multiple sclerosis (RRMS). It aims to see how well this therapy works for people in the Netherlands who have already been approved for it.
This study tests whether a medicine that targets a specific brain inflammation marker (TSPO) can help in people with certain types of multiple sclerosis. It focuses on safety and whether the target can be measured and influenced during treatment.
This trial uses your own blood stem cells to reboot your immune system, which may help stop multiple sclerosis attacks and slow disability. It is for people with active MS that has not responded well to other treatments.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
This early-phase study tests a stem cell transplant procedure for people with multiple sclerosis whose usual MS medicines have not worked or can’t be tolerated. The goal is to see if this approach can help control MS activity and progression, while checking for safety.
Hear when a new Multiple Sclerosis, Relapsing-Remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.